Delivery Order SPE2DB20D2104-SPE2DB22FT69R

Award Date 8/22/22
Potential Completion Date 8/23/22
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,948.36 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,083.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which enables the government to...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.80 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $23,225.40 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of March 6, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,695.76 Firm Fixed Price Delivery Order contract is for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription eye medication. The contract has an ultimate completion date of August 24, 2022. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,948.06 firm-fixed-price delivery order is for the drug RESTASIS 0.05% Eye Emulsion 60s. The award is not associated with a set-aside program. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,292.46 firm fixed-price delivery order is for the procurement of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication. The contract has a performance period through May 15, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award to Amerisourcebergen Drug Corp was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $3,944.23 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has an ultimate completion date of October 10, 2024. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor for this award, which is part of a larger Indefinite Delivery Contract (IDC) valued at up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,880.43 Firm Fixed Price Delivery Order is for the supply of RESTASIS 0.05% Eye Emulsion 60S, a prescription eye medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,286.88 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has an ultimate completion date of January 9, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB22FT69R
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,447.92 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription eye medication. This award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Amerisourcebergen also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These contracts enable the efficient government procurement of essential pharmaceutical and medical supplies to serve the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 2/27/25, 10:25 AM